These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
200 related items for PubMed ID: 20972470
1. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Hübel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rösler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kröger N. Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470 [Abstract] [Full Text] [Related]
2. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, Urbaniak-Kujda D, Dybko J, Zielinska P, Dabrowska-Iwanicka A, Werkun J, Rzepecki P, Wroblewska W, Wiktor-Jedrzejczak W. Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660 [Abstract] [Full Text] [Related]
3. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program. Selleslag D, Dierickx D, Breems DA, Huynh P, Van De Velde A, Meers S, Brouwer E, Mertens A. Acta Clin Belg; 2011 May; 66(3):200-4. PubMed ID: 21837928 [Abstract] [Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Stewart DA, Smith C, MacFarland R, Calandra G. Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941 [Abstract] [Full Text] [Related]
9. Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma. Micallef IN, Stiff PJ, Stadtmauer EA, Bolwell BJ, Nademanee AP, Maziarz RT, Partisano AM, Marulkar S, DiPersio JF. Am J Hematol; 2013 Dec; 88(12):1017-23. PubMed ID: 23907769 [Abstract] [Full Text] [Related]
11. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Jantunen E, Kuittinen T, Mahlamäki E, Pyörälä M, Mäntymaa P, Nousiainen T. Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864 [Abstract] [Full Text] [Related]
16. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT. Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037 [Abstract] [Full Text] [Related]
17. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Duarte RF, Shaw BE, Marín P, Kottaridis P, Ortiz M, Morante C, Delgado J, Gayoso J, Goterriz R, Martínez-Chamorro C, Mateos-Mazón JJ, Ramírez C, de la Rubia J, Achtereekte H, Gandhi PJ, Douglas KW, Russell NH. Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700 [Abstract] [Full Text] [Related]